Dr Reddy's Laboratories PE Ratio 2006-2018 | RDY

Current and historical price to earnings ratio for Dr Reddy's Laboratories (RDY) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Dr Reddy's Laboratories PE ratio as of September 17, 2018 is 26.44.
Dr Reddy's Laboratories Annual PE Ratio
Dr Reddy's Laboratories Quarterly PE Ratio
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $5.920B $2.204B
Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.556B 10.73
Teva Pharmaceutical Industries (TEVA) Israel $23.825B 6.66
Mylan (MYL) United Kingdom $19.184B 8.16
Bausch Health Cos (BHC) Canada $7.865B 5.87
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.469B 4.20
Supernus Pharmaceuticals (SUPN) United States $2.402B 25.70
Akorn (AKRX) United States $1.667B 8.25
Assembly Biosciences (ASMB) United States $0.876B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.849B 122.33
Homology Medicines (FIXX) United States $0.750B 0.00
CymaBay Therapeutics (CBAY) United States $0.722B 0.00
Voyager Therapeutics (VYGR) United States $0.603B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.540B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.443B 0.00
Corium (CORI) United States $0.334B 0.00
Teligent (TLGT) United States $0.198B 0.00
Sol-Gel Technologies (SLGL) Israel $0.130B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.117B 0.00
Aevi Genomic Medicine (GNMX) United States $0.077B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.064B 0.00
Evoke Pharma (EVOK) United States $0.056B 0.00
Versartis (VSAR) United States $0.053B 0.00
Acasti Pharma (ACST) Canada $0.020B 0.00
Agile Therapeutics (AGRX) United States $0.013B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.013B 0.00
China Pharma Holdings (CPHI) China $0.009B 0.00